ACT No. 46

HOUSE BILL NO. 378

BY REPRESENTATIVE MARINO

1	AN ACT
2	To amend and reenact R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) and to enact
3	R.S. 40:964(Schedule I)(A)(80) through (99), (C)(66), (E)(12), and (F)(29), and
4	(Schedule IV)(D)(15), relative to the Uniform Controlled Dangerous Substances
5	Law; to add certain substances to Schedules I and IV; to provide relative to
6	substances of vegetable origin or chemical synthesis in Schedule II; and to provide
7	for related matters.
8	Be it enacted by the Legislature of Louisiana:
9	Section 1. R.S. 40:964(Schedule II)(A)(1)(introductory paragraph) is hereby
10	amended and reenacted and R.S. 40:964(Schedule I)(A)(80) through (99), (C)(66), (E)(12),
11	and (F)(29), and (Schedule IV)(D)(15) are hereby enacted to read as follows:
12	§964. Composition of schedules
13	Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
14	40:962, consist of the following drugs or other substances, by whatever official
15	name, common or usual name, chemical name, or brand name designated:
16	SCHEDULE I
17	A. Opiates. Unless specifically excepted or unless listed in another schedule,
18	any of the following opiates, including their isomers, esters, ethers, salts, or salts of
19	isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,
20	or salts is possible within the specific chemical designation:
21	* * *
22	(80) Phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide)

HB NO. 378 ENROLLED

I	(81) para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-
2	yl)propanamide)
3	(82) Thiofuranylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene
4	-2-carboxamide)
5	(83) beta-methylfentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-
6	yl)propanamide)
7	(84) beta-phenylfentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-
8	diphenylpropanamide)
9	(85) 2-fluoro-orthofluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-
10	N-(2-fluorophenyl)propanamide)
11	(86) 4-methylacetylfentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-
12	phenylacetamide)
13	(87) Orthomethylacetylfentanyl (N-(2-methylphenyl)-N-(1-
14	phenethylpiperidin-4-yl)acetamide)
15	(88) Orthomethylmethoxyacetylfentanyl (2-methoxy-N-(2-methylphenyl)-N-
16	(1-phenethylpiperidin-4-yl)acetamide)
17	(89) Orthofluoroacrylfentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-
18	4-yl)acrylamide)
19	(90) Fentanyl carbamate (ethyl(1-phenethylpiperidin-4-yl)(phenyl)
20	<u>carbamate)</u>
21	(91) para-fluorofuranylfentanyl (N-(4-fluorophenyl)-N-(1-
22	phenethylpiperidin-4-yl)furan-2-carboxamide)
23	(92) Isotonitazene (N,N-diethyl-2-[(4-isopropoxyphenyl)methyl]-5-nitro-
24	1H-benzimidazole-1-ethanamine)
25	(93) Metonitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-
26	benzimidazole-1-ethanamine)
27	(94) Butonitazene (N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1H-
28	benzimidazole-1-ethanamine)
29	(95) Flunitazene (N,N-diethyl-2-(4-fluorophenyl)methyl]-5-nitro-1H-
30	benzimidazole-1-ethanamine)

	HB NO. 378 ENROLLED
1	(96) Protonitazene (N,N-diethyl-2-[(4-propoxyphenyl)methyl]-5-nitro-1H-
2	benzimidazole-1-ethanamine)
3	(97) N-pyrrolidino etonitazene (2-[(4-ethoxyphenyl)methyl]-5-nitro-1-
4	[2-(pyrrolidino-1-yl)ethyl]-1H-benzimidazole)
5	(98) Etodesnitazene (N,N-diethyl-2-[(4-ethoxyphenyl)methyl]-1H-
6	benzimidazole-1-ethanamine)
7	(99) Metodesnitazene (N,N-diethyl-2-[(4-methoxyphenyl)methyl]-1H-
8	benzimidazole-1-ethanamine)
9	* * *
10	C. Hallucinogenic substances. Unless specifically excepted or unless listed
11	in another schedule, any material, compound, mixture, or preparation, which
12	contains any quantity of the following hallucinogenic substances, or which contains
13	any of their salts, isomers, or salts of isomers, whenever the existence of such salts,
14	isomers, or salts of isomers is possible within the specific chemical designation, for
15	purposes of this Paragraph only, the term "isomer" includes the optical, position, and
16	geometric isomers:
17	* * *
18	(66) para-methoxymethamphetamine (PMMA)
19	* * *
20	E. Stimulants. Unless specifically excepted, or contained within a
21	pharmaceutical product approved by the United States federal Food and Drug
22	Administration, or unless listed in another schedule, any material, compound,
23	mixture, or preparation which contains any quantity of the following substances
24	having a stimulant effect on the central nervous system including its salts, isomers,
25	esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such
26	salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible

* * *

within the specific chemical designation:

27

28

29

(12) 4,4-dimethylaminorex (4,4-DMAR)

HB NO. 378 ENROLLED

1	F. Synthetic cannabinoids. Unless specifically excepted, or contained within
2	a pharmaceutical product approved by the United States Food and Drug
3	Administration, or unless listed in another schedule, any material, compound,
4	mixture, or preparation, which contains any quantity of a synthetic cannabinoid
5	found to be in any of the following individual compounds or chemical groups, or any
6	of those individual compounds or groups which contain any synthetic cannabinoid
7	salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the
8	existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs
9	is possible within the specific compounds or chemical groups:
10	* * *
11	(29) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-B]
12	pyridine-3-carboxamide [5FCUMYL-P7AICA]
13	* * *
14	SCHEDULE II
15	A. Substances of vegetable origin or chemical synthesis. Unless specifically
16	excepted or unless listed in another schedule, any of the following substances
17	whether produced directly or indirectly by extraction from substances of vegetable
18	origin, or independently by means of chemical synthesis, or by a combination of
19	extraction and chemical synthesis:
20	(1) Opium and opiate, and any salt, compound, derivative, or preparation of
21	opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan,
22	nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β -naltrexol, and
23	naltrexone, and samidorphan, and their respective salts, but including the following:
24	* * *
25	SCHEDULE IV
26	* * *
27	D. Stimulants. Unless specifically excepted or unless listed in another
28	schedule, any material, compound, mixture, or preparation which contains any
29	quantity of the following substances, including its salts, isomers, and salts of
30	isomers:

Page 4 of 5

31

1	(15) Serdexmethylphenidate
2	* * *
3	Section 2. The Louisiana State Law Institute is hereby authorized and directed to
4	renumber the substances in R.S. 40:964(Schedule I)(A),(C), and (E) and (Schedule V)(D)
5	to ensure that such substances are in alphabetical order.
	SPEAKER OF THE HOUSE OF REPRESENTATIVES
	PRESIDENT OF THE SENATE
	GOVERNOR OF THE STATE OF LOUISIANA

ENROLLED

HB NO. 378

APPROVED: _____